Free Trial
OTCMKTS:ACUR

Acura Pharmaceuticals (ACUR) Stock Price, News & Analysis

Acura Pharmaceuticals logo
$0.0015
+0.00 (+7.14%)
(As of 11/1/2024 08:57 PM ET)

About Acura Pharmaceuticals Stock (OTCMKTS:ACUR)

Key Stats

Today's Range
$0.0015
$0.0015
50-Day Range
N/A
52-Week Range
$0.00
$0.58
Volume
1,000 shs
Average Volume
2,658 shs
Market Capitalization
$99,523.50
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.

Receive ACUR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acura Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACUR Stock News Headlines

Ticking time bomb. Detonation Nov 5
Porter Stansberry’s viral Breaking Point 2024 broadcast has now been by tens of thousands of Americans who finally understand the grim reality of our next election. With November 5 just around the corner, it’s imperative for your financial future that you read Porter’s message below now and then watch Breaking Point before it’s too late.
See More Headlines

ACUR Stock Analysis - Frequently Asked Questions

Acura Pharmaceuticals' stock was trading at $0.0001 on January 1st, 2024. Since then, ACUR shares have increased by 1,400.0% and is now trading at $0.0015.
View the best growth stocks for 2024 here
.

Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) issued its earnings results on Friday, February, 28th. The specialty pharmaceutical company reported $0.00 earnings per share for the quarter. The specialty pharmaceutical company earned $1.32 million during the quarter.

Acura Pharmaceuticals subsidiaries include these companies: Acura Pharmaceutical Technologies Inc..

Shares of ACUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acura Pharmaceuticals investors own include Denali Therapeutics (DNLI), Ekso Bionics (EKSO), Matinas BioPharma (MTNB), VIVUS (VVUS), Corbus Pharmaceuticals (CRBP), Fulcrum Therapeutics (FULC) and Adamis Pharmaceuticals (ADMP).

Company Calendar

Last Earnings
2/28/2020
Today
11/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:ACUR
Previous Symbol
NASDAQ:ACUR
CUSIP
00509L70
Employees
10
Year Founded
1935

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.56 million

Miscellaneous

Free Float
52,947,000
Market Cap
$99,523.50
Optionable
Not Optionable
Beta
1.62

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (OTCMKTS:ACUR) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners